Breaking News

DPT Completes Corrective Actions

March 20, 2013

FDA closes out investigation of Lakewood site

DPT Laboratories has received notification from the FDA on February 19, 2013, signaling the completion of DPT’s corrective actions taken at its Lakewood, NJ facility in response to the warning letter received on August 27, 2012. The letter also communicated that the Lakewood site is compliant with FDA regulations.
 
“We are pleased to have this issue behind us and appreciate the confidence our new and existing customers demonstrated in us during this time,” said Eugene Ciolfi, DPT vice president and general manager.  “I am excited and optimistic about the opportunities ahead of us in 2013.”
 
“This resolution has strengthened DPT,” said Paul Johnson, DPT Group president and chief operating officer. “Our commitment to quality and continuous improvement will remain a priority as we continue building a world-class business.”

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Getting Real

    Michael Pollock, PPD||November 17, 2015
    Partnering for clinical and real-world evidence studies

  • Bringing Transparency and Collaboration to CRO Oversight

    Bringing Transparency and Collaboration to CRO Oversight

    Craig Morgan , goBalto Inc. ||November 17, 2015
    Relationships between sponsors and CROs are getting stronger